Terminal
Spotlight
Cashu Research

← Back to Terminal

Stocks
Healthcare
NASDAQ
REVB

Market Cap: $2.01M

RI

Revelation Biosciences, Inc.

REVB

NASDAQ (NASDAQ Capital Market)USD

Overview News Analyst Reports Financials Politician Trades Insider Trades Executive

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

Stocks About Advertisers Brokers Contact

Legal

Terms of Service Privacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

News

Revelation Biosciences Initiates 1-for-16 Reverse Split and Advances CKD Clinical Trial

Revelation Biosciences Advances Clinical Research Amid Structural Changes Revelation Biosciences Inc. is poised for significant developments in its clinical research and corporate structure as it prep…

Cashu Finance·almost 2 years ago

Revelation Biosciences Advances CKD Research with Phase 1b Trial Amid Reverse Stock Split

Revelation Biosciences Advances in Chronic Kidney Disease Research Amid Structural Changes Revelation Biosciences Inc. is making significant strides in its research efforts, specifically with the init…

Cashu Finance·almost 2 years ago

Revelation Biosciences Begins Clinical Study for Chronic Kidney Disease Treatment with Gemini

Revelation Biosciences Launches Clinical Study to Combat Chronic Kidney Disease Revelation Biosciences, Inc. has officially commenced its PRIME Phase 1b clinical study, a significant initiative aimed…

Cashu Finance·almost 2 years ago

Revelation Biosciences Initiates Clinical Trial for Chronic Kidney Disease Treatment with Gemini Formulation

Revelation Biosciences Launches Promising Clinical Trial for Chronic Kidney Disease Treatment Revelation Biosciences, Inc. initiates its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b c…

Cashu Finance·almost 2 years ago

Revelation Biosciences Boosts Funding and Growth with Strategic Warrant Exercise for Immunity Therapies

Revelation Biosciences Advances Immunity-Based Therapeutics with Strategic Warrant Exercise Revelation Biosciences, Inc., a clinical-stage life sciences company, focuses on harnessing trained immunity…

Cashu Finance·almost 2 years ago

Revelation Biosciences Receives FDA Approval for Gemini in Kidney Disease Treatment

Revelation Biosciences Advances Kidney Disease Treatment with FDA Approval Revelation Biosciences, Inc. achieves a significant milestone by receiving acceptance of its investigational new drug (IND) a…

Cashu Finance·almost 2 years ago

Revelation Biosciences Advances Gemini for Chronic Kidney Disease with FDA IND Approval

Revelation Biosciences Advances Clinical Development of Gemini for Chronic Kidney Disease Revelation Biosciences, Inc., a clinical-stage life sciences company specializing in trained immunity therapie…

Cashu Finance·almost 2 years ago

Revelation Biosciences Achieves GMP Milestone for Gemini Drug, Advancing CKD Treatment Development

Revelation Biosciences Achieves Key Manufacturing Milestone for Gemini Drug Product Revelation Biosciences, Inc. has reached a significant milestone in its development of the Gemini drug product, havi…

Cashu Finance·almost 2 years ago

Revelation Biosciences Achieves GMP Milestone for Chronic Kidney Disease Treatment with Gemini

Revelation Biosciences Achieves Key Manufacturing Milestone for Chronic Kidney Disease Treatment Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company focused on innovative therapie…

Cashu Finance·almost 2 years ago

Revelation Biosciences Advances Gemini Drug for Immune Modulation and Chronic Kidney Disease

Revelation Biosciences Advances in Immune Modulation with Gemini Drug Development Revelation Biosciences, Inc. is making significant strides in the field of immune modulation with its clinical-stage d…

Cashu Finance·almost 2 years ago